Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | OXTR | P30559 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.41 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12422828 | 0.75 | HDAC1 (0.42) | SMN1; SMN2 | |
| SCHEMBL22187008 | 0.70 | HPGD (0.69) | HPGDALDH1A1GLAALOX12SMN1; SMN2 | |
| SCHEMBL28476929 | 0.69 | OXTR (0.50) | HPGDOXTRALDH1A1AVPR1ASMN1; SMN2 | |
| SCHEMBL28473802 | 0.69 | OXTR (0.50) | HPGDOXTRALDH1A1AVPR1ASMN1; SMN2 | |
| SCHEMBL28473805 | 0.69 | OXTR (0.50) | HPGDOXTRALDH1A1AVPR1ASMN1; SMN2 | |
| SCHEMBL18357628 | 0.69 | HPGD (0.61) | HPGDOXTRALDH1A1GLAALOX12 | |
| SCHEMBL22187009 | 0.68 | HPGD (0.49) | HPGDOXTRALDH1A1GLAALOX12 | |
| SCHEMBL18088562 | 0.68 | OXTR (0.44) | HPGDOXTRALDH1A1AVPR1AAVPR2 | |
| SCHEMBL22074352 | 0.67 | ALDH1A1 (0.48) | HPGDOXTRALDH1A1AVPR1AAVPR2 | |
| SCHEMBL10473220 | 0.67 | ALDH1A1 (0.49) | HPGDOXTRALDH1A1AVPR1AAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977020-B2 | Electrophotographic photoreceptor containing enamine compound, image formation apparatus provided with the same, enamine compound and method for producing the same | SHARP KABUSHIKI KAISHA (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977020-B2 | Electrophotographic photoreceptor containing enamine compound, image formation apparatus provided with the same, enamine compound and method for producing the same | SHARP KABUSHIKI KAISHA (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080286671-A1 | Electrophotographic photoreceptor containing enamine compound, image formation apparatus provided with the same, enamine compound and method for producing the same | SHARP KABUSHIKI KAISHA (JP) | 2008-11-20 | — | — | US | disclosed |
| US-20080286671-A1 | Electrophotographic photoreceptor containing enamine compound, image formation apparatus provided with the same, enamine compound and method for producing the same | SHARP KABUSHIKI KAISHA (JP) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286671-A1 | Electrophotographic photoreceptor containing enamine compound, image formation apparatus provided with the same, enamine compound and method for producing the same | SLC1A2, SLC1A1, SLC18A1 | HPGD 596/4885OXTR 3688/4885ALDH1A1 869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.